Article: ESTORRA(TM) Six-Month Study Data Receives Rapid Peer Review and Publication in the Journal SLEEP.

Sepracor Inc. today announced that data from its six-month, Phase III, randomized, double-blind, placebo-controlled safety and efficacy study of ESTORRA(TM) brand eszopiclone for the treatment of chronic insomnia was published in the journal SLEEP, the official publication of the Associated Professional Sleep Societies. This manuscript was deemed by the publishers of SLEEP to be of sufficient scientific importance and interest to the clinical and research community to warrant rapid peer review and publication.

"The results of this study demonstrate that nightly use of ESTORRA provided statistically significant improvements compared with placebo in patient ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!